Ibrutinib in Previously Treated Waldenström's Macroglobulinemia

Key Findings

• ●Overall response rate 90.5%, major response rate 73% in previously treated WM
• ●MYD88 and CXCR4 status affected response: MYD88mut/CXCR4wt had 100% ORR
• ●Led to FDA approval of ibrutinib for WM

Referenced in (1 disease)